Christiaan JM Vrints

Emeritus full professor University of Antwerp
Past Chairman dept of Cardiology Antwerp Univ Hospital
Past EiC Eur Heart J Acute Cardiovasc Care

[EHJ Editor-in-Chief @ehj_ed]

Coronary microvascular obstruction: the "no-reflow" problem that haunts STEMI care. New ESC clinical consensus on pathophysiology, prevention & management: a must-read. Read more in #EHJ.
https://t.co/WWlcFSfVyj
#cardiotwitter @ESC_Journals @escardio

[Davide Capodanno @DFCapodanno]

This state-of-the-art review provides a comprehensive overview of the pathophysiological mechanisms underlying the no-reflow/slow-flow phenomenon, covering invasive and non-invasive diagnostic tools, pharmacological and interventional treatment strategies, and the key clinical gaps that still need to be addressed in the field. https://t.co/glYW3u2X2z

[Carlos Collet MD PhD @ColletCarlos]

Unique opportunity!

[Christiaan JM Vrints @cvrints]

Another piece of evidence from ORBITA-2 supporting functional assessment before PCI, as recommended by the 2024 ESC CCS guidelines: Focal and Diffuse CAD Patterns and Placebo-Controlled Angina Relief With PCI 10.1016/j.jacc.2026.02.5126

[American Heart Association @American_Heart]

The American Heart Association mourns the passing of the legendary cardiologist Eugene Braunwald, M.D., widely recognized as one of the most influential figures in the history of cardiovascular medicine. Over seven decades, his work reshaped the understanding and treatment of heart disease, leading many to call him the father of modern cardiology.

Braunwald was a lifelong contributor to the American Heart Association, helping advance its research and scientific mission, and was honored with some of the Association’s highest honors for his lasting influence on cardiovascular care and research. His influence extended well beyond his own discoveries, as generations of Association‑supported investigators, clinicians and academic leaders were trained by Braunwald or guided by the clinical trial standards and mentorship models he helped establish.

https://t.co/ieZuHYMyOP

[ACVCPresident @ACVCPresident]

You have a busy schedule?
Not being able to attend #ACVC26 ?
Don't worry, we got you covered.☑️

Listen to the wrap up of hot topics of this year congress selected beautifully by @ATycinska @JaninePoss @rafavidalperez

https://t.co/midkxqzFs2

#ACVCPodcast @escardio

[EuroIntervention @EuroInterventio]

The new issue is online, including:

• State-of-the-Art on antiplatelet pretreatment
• Prognostic impact of high ischaemic risk and complex PCI
• Updated coronary thrombectomy technique
and more

🔗https://t.co/OtUqwpLx9m

#CardioTwitter #interventionalcardiology #cardiomed

@cvrints @g_giustinoMD @DLBHATTMD @Gurleen_Kaur96 @Drroxmehran @piccoloraf @espogiov @JuanFIglesias1

[Christiaan JM Vrints @cvrints]

@DFCapodanno Nice review, but conceptually rooted in the 20th century. Further progress may come not from refining antithrombotic therapies, but from strategies aimed at detecting vulnerable — most often nonobstructive — atheroma, and from novel anti-atherosclerotic therapies.

[ACVCPresident @ACVCPresident]

The perfect ending of an amazing day 1 at #ACVC26
🎯Recognition Awards go to @rafavidalperez Prof Josep Masip, Prof Marco Tubaro, Professor Hector Bueno and @JorgeNuche
🎯 #ACVC_ESC Lifetime Award goes to @thiele_holger

Moderated by @Sofiegevaert
@sighalvo
Congratulations to all🎉🎉🎉

@HannahSchaubro1
@sionis_a
@escardio @drmilicaa @franciscojlk

[Christiaan JM Vrints @cvrints]

@ColletCarlos Or IVUS/OCT?

[Christiaan JM Vrints @cvrints]

@DFCapodanno @ihtanboga @ehj_ed @thiele_holger Du choc des ideas jaillit la lumiere! Let’s keep sparking ideas and debates on cardio X!

[EHJ Editor-in-Chief @ehj_ed]

Outcomes of heart failure with reduced, mildly reduced, or preserved ejection fraction: the ESC HF III registry. Read more in EHJ.

https://t.co/hwEmSaUG0b

#EHJ #cardiotwitter #heart #failure #preserved #ejection #fraction @ESC_journals @escardio

[Christiaan JM Vrints @cvrints]

@ColletCarlos @JAHA_AHA @JACCJournals @TCTConference @crfheart @PCRonline 🤔Which contrast medium was used? I remember seeing flocculation when papaverin was mixed with Ioxaglic acid (Hexabrix).

[EHJACVC Editor-in-Chief @EHJACVCEiC]

The clock is ticking - join as at #ACVC26

REGISTER HERE 👇
https://t.co/bAAWOW70au

@escardio @ACVCPresident @drmilicaa @ESC_Journals @maria_bergami @FH_Verbrugge @franciscojlk @ehj_ed @rafavidalperez @sionis_a @HannahSchaubro1 @JasonKatzMD @seanvandiepen @cvrints

[Christiaan JM Vrints @cvrints]

@Richmuskheart1 Yes, a bike dynamo. Its wire always gets disconnected. Very annoying when it is dark!

[Carlos Collet MD PhD @ColletCarlos]

The SCAPIS study published in JAMA

~25,000 🇸🇪 participants, ~8 years follow-up. Adding coronary CT angiography #CCTA plaque information improved event prediction beyond clinical risk and calcium score.

This is the first study showing the added value of CCTA on top of the calcium score for risk prediction.

🎯 What to look for: lipidic soft (non-calcified) plaque.
👀 Practical takeaway: Consider a CT angiography for risk stratification on top of the calcium score.

Link: https://t.co/EOK6DH6PF6

🎥 Posting my avatar summarizing the study.

[ACVCPresident @ACVCPresident]

Holiday season is at the end and do you know what comes next?
The first @escardio congress of the year #ACVC26
TOMORROW is the deadline for late breaking clinical trial submissions - if you have some raw research you still have time until noon CET
And don't forget to register for an early fee discount - 7 days left.
See you 🔜 in Lisbon. 🇵🇹 https://t.co/yLMhe0Hm7B

[Christiaan JM Vrints @cvrints]

@ColletCarlos @JACCJournals @crfheart Correct point of view, but you meant epicardial coronary artery disease.

[EHJ Editor-in-Chief @ehj_ed]

Non-ST-elevation acute coronary syndrome gets a fresh deep dive, revealing its full spectrum and why tailored, smarter management matters more than ever. Read more in #EHJ. https://t.co/pLptkxyZs2
#ACS #cardiotwitter @ESC_Journals @escardio